Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.
The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.
McGuire Daniel Patrick reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals reported that SVP, General Counsel and Secretary Daniel Patrick McGuire received a grant of 80,000 shares of common stock underlying a restricted stock unit (RSU) award at no cash cost per share. His direct ownership after the grant is 109,982 common shares.
The RSU award vests in four equal annual installments beginning on June 4, 2027, as long as he remains continuously employed through each vesting date. Vested shares will be delivered on the first permissible trading day on or after each vesting date, making this a routine equity-based compensation grant rather than an open-market trade.
Chrousos Phaedra reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Phaedra Chrousos received a grant of 41,600 shares of Common Stock in the form of time-based restricted stock units. The award was granted at no cash cost per share and is part of her equity compensation.
All 41,600 RSU shares will vest on June 4, 2027, provided she continues to serve the company through that date. Following this grant, she directly holds 164,950 shares of Vanda Pharmaceuticals common stock.
Duncan Charles Cliff reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Charles Cliff received a grant of 41,600 shares of common stock in the form of time-based restricted stock units at no purchase price. These RSUs vest in full on June 4, 2027 if he remains in continuous service, bringing his direct holdings to 98,701 shares.
DUGAN RICHARD W reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Richard W. Dugan reported an equity compensation grant in the form of restricted stock units. On June 4, 2026, he was awarded 41,600 shares of common stock underlying a time-based RSU that vests 100% on June 4, 2027, contingent on continuous service. Following this grant, Dugan holds 219,054 shares of Vanda common stock directly.
Ward Anne Sempowski reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Anne Sempowski Ward received an equity award covering 41,600 shares of common stock in the form of time-based restricted stock units. The award was granted at no cash cost to her and is scheduled to vest in full on June 4, 2027, if she continues serving the company through that date. After this grant, she is reported as beneficially owning 160,667 shares of Vanda common stock directly.
Vanda Pharmaceuticals director Honore Tage received a grant of 41,600 shares of common stock through a restricted stock unit (RSU) award. The RSUs are time-based and will vest 100% on June 4, 2027, if Tage continues to provide service to the company through that date.
Following this grant, Tage directly holds 135,069 shares of Vanda Pharmaceuticals common stock. Because the shares were awarded as equity compensation at no cash cost, this filing reflects a compensation-related acquisition rather than an open-market purchase.
Mitchell Stephen Ray reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray received a grant of 41,600 shares of Common Stock through a time-based restricted stock unit award at no cost. All RSUs will vest on June 4, 2027 if he remains in continuous service. Following this award, he directly owns 112,846 shares.
Vanda Pharmaceuticals executive Daniel Patrick McGuire, SVP, GC and Secretary, filed an initial Form 3 reporting his beneficial ownership of common stock and restricted stock units. The holdings include several RSU awards that vest in equal annual installments between July 29, 2026 and March 1, 2029, contingent on continued employment.
Vanda Pharmaceuticals Inc. reported the results of its 2026 annual stockholder meeting held on June 4, 2026. Stockholders elected three Class II directors—Richard W. Dugan, Charles C. Duncan, Ph.D., and Anne Sempowski Ward—to serve until the 2029 annual meeting.
PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved, on an advisory, non-binding basis, the compensation of the company’s named executive officers and approved an amendment to the 2016 Equity Incentive Plan increasing the shares authorized for issuance.
A quorum was present, with 48,509,906 of 60,135,062 eligible common shares, or approximately 80.7%, represented in person or by proxy.
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray reported a charitable gift of 25,836 shares of Common Stock on a Form 4. The transaction used code "G" for a bona fide gift and carried a price of $0.00 per share, meaning no sale proceeds were received. After this donation to a charitable organization, Ray directly holds 71,246 shares of Vanda common stock. This is a non-market transaction and does not reflect open-market buying or selling activity.